NCT06584435View on ClinicalTrials.gov

A Study of Toripalimab in Adjuvant Therapy After Resection of High-risk Renal Cancer Tumors

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 1, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

March 3, 2025

Conditions
High-risk Renal Cell Carcinoma
Interventions
DRUG

Tremelimumab

Tremelimumab is administered intravenously at a fixed dose of 240 mg every 3 weeks for 1 treatment cycle until tumor recurrence or intolerable toxic effects.

Trial Locations (1)

300211

RECRUITING

Changyi Quan, Tianjin

All Listed Sponsors
lead

Tianjin Medical University Second Hospital

OTHER